757 related articles for article (PubMed ID: 7683702)
1. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of risperidone on positive features of schizophrenia.
McEvoy JP
J Clin Psychiatry; 1994 May; 55 Suppl():18-21. PubMed ID: 7520904
[TBL] [Abstract][Full Text] [Related]
4. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
5. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
López Ibor JJ; Ayuso JL; Gutiérrez M; Guimon J; Herraiz ML; Chinchilla A; Ayuso JL; González Pinto A; Eguiluz I; Fernández A
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(4):165-72. PubMed ID: 8984849
[TBL] [Abstract][Full Text] [Related]
6. Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.
Czobor P; Volavka J
J Clin Psychopharmacol; 1993 Oct; 13(5):332-42. PubMed ID: 7693770
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
Yen YC; Lung FW; Chong MY
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
[TBL] [Abstract][Full Text] [Related]
8. Risperidone: clinical safety and efficacy in schizophrenia.
Borison RL; Pathiraja AP; Diamond BI; Meibach RC
Psychopharmacol Bull; 1992; 28(2):213-8. PubMed ID: 1381102
[TBL] [Abstract][Full Text] [Related]
9. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
Kopala LC; Honer WG
J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
[No Abstract] [Full Text] [Related]
10. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
[TBL] [Abstract][Full Text] [Related]
11. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
12. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
13. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
14. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
Peuskens J
Br J Psychiatry; 1995 Jun; 166(6):712-26; discussion 727-33. PubMed ID: 7545060
[TBL] [Abstract][Full Text] [Related]
15. Negative symptoms in schizophrenia: assessment of the effect of risperidone.
Schooler NR
J Clin Psychiatry; 1994 May; 55 Suppl():22-8. PubMed ID: 7520905
[TBL] [Abstract][Full Text] [Related]
16. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
[TBL] [Abstract][Full Text] [Related]
17. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.
Keegan D
Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S46-52. PubMed ID: 7533051
[TBL] [Abstract][Full Text] [Related]
18. Extrapyramidal side effects and tolerability of risperidone: a review.
Owens DG
J Clin Psychiatry; 1994 May; 55 Suppl():29-35. PubMed ID: 7520906
[TBL] [Abstract][Full Text] [Related]
19. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
[TBL] [Abstract][Full Text] [Related]
20. Risperidone in the treatment of schizophrenia.
Marder SR; Meibach RC
Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
